Clinical Trial

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Completed
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-10.
Status change: Active, Not Recruiting → Completed 2026-05-18
Trial Details
NCT Number NCT07073690
Lead Sponsor Bristol-Myers Squibb
Conditions Myelodysplastic Syndromes
Enrollment 88 participants
Start Date 2025-04-18
Primary Completion 2026-05-12 (estimated)
Study Completion 2026-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-19